CLC bio to Launch High-Performance Computing ‘Genomics Machine’ at ISMB



By Bio-IT World staff

June 22, 2009 | Danish informatics company CLC bio will be unveiling the CLC Genomics Machine at the 17th annual conference on Intelligent Systems for Molecular Biology (ISMB) in Stockholm at the end of this month, Bio-IT World has learned.

The Genomics Machine is billed as the “first turnkey solution for analyzing and visualizing next-generation sequencing data,” according to the company.  The solution consists of a hardware platform, pre-installed software -- including accelerated algorithms for next-gen data analysis -- and an enterprise level database.

CEO Thomas Knudsen told Bio-IT World: "We have gone in a different direction than all other teams developing and refining algorithms for analyzing the massive amounts of data coming from the NGS instruments. Instead of constantly scaling up your hardware to the point where you need very big clusters or a cloud computing setup in order to do de novo assembly of large genomes, our scientific developers started from scratch and thought out some quite clever ways of handling those large amounts of data -- to the point where a single CLC Genomics Machine can handle these tasks without breaking a sweat."

During initial benchmark testing, CLC bio claims to have produced one-fold coverage of a human genome assembly to the reference can be completed in around one hour. The solution also includes classic bioinformatics algorithms such as like BLAST, HMMsearch, HMMpfam, Smith-Waterman and ClustalW. Again, performance benchmarks algorithms are said to be favorable compared to a popular off-the-shelf biocomputing FPGA solution.

Lasse Goerlitz, CLC bio’s head of global PR and marketing, said he was excited to debut this solution at ISMB. “It's a true testament to the very high scientific level of our development team, accomplishing something previously unseen anywhere in the world,” said Goerlitz. “I think it goes well with another expression we'll be showcasing in Stockholm: ‘Rocket Science is for kids. Bioinformatics is for scientists!’"

Knudsen says the Genomics Machine marks “a big push into high-performance computing for life sciences” and predicts that existing biocomputing solutions “essentially will be left in the dark with the performance we’re going to deliver.”

CLC bio expects soon to announce a partnership “with one of the premier technologies available” to expand its enterprise platform.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .